Interface Bio was co-founded by two Stanford PhDs with a shared belief that microbes are the world’s most powerful chemists, thanks to the billions of years spent co-evolving with mammals. Our team’s vision is to integrate the microbiome into modern medicine with a specific focus on treatment of inflammatory disease.
Hannah C. Wastyk, Ph.D.
Co-founder, CEO
Hannah graduated from Stanford in 2021 with her PhD in Bioengineering. Armed with a background in experimental biochemistry, she shifted her focus during grad school to study the causal relationships between the human microbiome and immune system using multi-omics data sets with machine learning and statistical methods.
Will Van Treuren, Ph.D.
Co-founder, CSO
Will graduated from Stanford in 2020 with his PhD in Microbiology and Immunology. After spending several years in Rob Knight’s lab developing bioinformatic tools, he spent his PhD developing culturomics and small-molecule metabolomics methods to identify microbe and microbe-host co-metabolites.
Stephanie Tan, Ph.D.
Lead Chemical Biologist
Stephanie graduated from the University of Toronto in 2022 with her PhD in Biochemistry. Her work focused on identifying microbial products with antibacterial and anti-inflammatory properties using LC-MS.
Elizabeth Brown, B.S.
Research Associate
Elizabeth graduated from UCSD with a B.S. degree in Biology. She was the first hire at UCSD’s microbiome core and helped run their high-throughput sequencing and metabolomics pipeline.
Scientific Advisory Board
Our board has extensive drug development and research experience.
